Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) CFO Sells $807,800.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CFO Ivan Hyep sold 28,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.85, for a total transaction of $807,800.00. Following the completion of the transaction, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. The trade was a 17.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ivan Hyep also recently made the following trade(s):

• On Thursday, May 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.42, for a total transaction of $187,864.00.
• On Tuesday, April 21st, Ivan Hyep sold 9,200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.00, for a total transaction of $211,600.00.

Bicara Therapeutics Price Performance

Shares of BCAX opened at $28.91 on Monday. The company has a market cap of $1.90 billion, a P/E ratio of -10.40 and a beta of -0.81. Bicara Therapeutics Inc. has a fifty-two week low of $9.47 and a fifty-two week high of $30.99. The firm’s 50 day moving average price is $23.43 and its 200 day moving average price is $20.11.

Bicara Therapeutics (NASDAQ:BCAX) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.21). Research analysts forecast that Bicara Therapeutics Inc. will post -3.48 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. raised its position in shares of Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock worth $54,472,000 after acquiring an additional 2,771,868 shares in the last quarter. Janus Henderson Group PLC acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $44,484,000. Vestal Point Capital LP increased its stake in Bicara Therapeutics by 80.6% in the second quarter. Vestal Point Capital LP now owns 5,000,000 shares of the company’s stock valued at $46,450,000 after purchasing an additional 2,231,025 shares during the last quarter. Franklin Resources Inc. acquired a new stake in Bicara Therapeutics during the fourth quarter worth approximately $27,265,000. Finally, State Street Corp raised its holdings in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after purchasing an additional 1,059,260 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BCAX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Morgan Stanley increased their price target on Bicara Therapeutics from $36.00 to $37.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Wells Fargo & Company boosted their price objective on Bicara Therapeutics from $11.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Bicara Therapeutics in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.